<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04886050</url>
  </required_header>
  <id_info>
    <org_study_id>LG-GDCL007</org_study_id>
    <nct_id>NCT04886050</nct_id>
  </id_info>
  <brief_title>Relative Bioavailability Study to Assess an LC350189 Tablet Compared to an LC350189 Capsule in Healthy Adults</brief_title>
  <official_title>A Phase 1, Open-Label, Randomized, Single-Dose Crossover Study to Evaluate the Bioavailability of an LC350189 Tablet Relative to an LC350189 Capsule in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LG Chem</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LG Chem</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, randomized, crossover, single dose study. Two single doses of&#xD;
      LC350189(tablet or capsule formulations) will be administered with a washout period of at&#xD;
      least 4-day between the doses to investigate the relative bioavailability of LC350189 after&#xD;
      administration via tablet formulation compared with capsule formulation and to evaluate basic&#xD;
      systemic pharmacokinetic parameters of the tablet formulation compared to the capsule&#xD;
      formulation of LC350189.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The relative bioavailability of LC350189 after administration via tablet formulation compared with capsule formulation by assessment of the area under the plasma concentration-time curve from zero to infinity for the tablet formulation capsule formation</measure>
    <time_frame>From baseline up to Day 8 (72 hours post on Day 5)</time_frame>
    <description>Blood sample for determination of plasma concentration of LC350189 will be collected at pre-dose and 0.5,1,2,4,6,8,16,24,36,48, and 72 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse events</measure>
    <time_frame>From baseline up to Day 8</time_frame>
    <description>Safety assessment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Gout</condition>
  <condition>Hyperuricemia</condition>
  <arm_group>
    <arm_group_label>LC350189 Formulation A (Tablet)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each subject will be administered a single LC350189 200mg (QD) Tablet on Day 1 and Day 5, respectively.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LC350189 Formulation B (Capsule)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each subject will be administered two LC350189 100mg (QD) Capsules (2 x 100-mg capsules) on Day 1 or Day 5, respectively.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LC350189 Tablet</intervention_name>
    <description>Subject will receive an LC350189 Tablet as single dose on Day 1 or Day 5</description>
    <arm_group_label>LC350189 Formulation A (Tablet)</arm_group_label>
    <other_name>LC350189</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LC350189 Capsule</intervention_name>
    <description>Subject will receive an LC350189 Capsule as single dose on Day 1 or Day 5</description>
    <arm_group_label>LC350189 Formulation B (Capsule)</arm_group_label>
    <other_name>LC350189</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The subject is male or female 18 to 50 years of age, inclusive.&#xD;
&#xD;
          -  The subject has a body mass index 18 to 32 kg/m2, inclusive, at screening.&#xD;
&#xD;
          -  The subject is judged by the investigator to be in good general health, as determined&#xD;
             by medical history, clinical laboratory assessments, vital sign measurements, 12 lead&#xD;
             electrocardiogram (ECG) results, and physical examination findings at screening.&#xD;
&#xD;
          -  The subject agrees to comply with all protocol requirements.&#xD;
&#xD;
          -  The subject is able to provide written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The subject has a medical history with any issues affecting absorption or metabolism,&#xD;
             as judged by the investigator.&#xD;
&#xD;
          -  The subject has a positive test result for hepatitis B surface antigen, hepatitis C&#xD;
             virus antibody, or human immunodeficiency virus types 1 or 2 antibodies at screening.&#xD;
&#xD;
          -  The subject has a positive test result for SARS-CoV-2 at screening.&#xD;
&#xD;
          -  The subject has used any prescription (excluding hormonal birth control and hormone&#xD;
             replacement therapy) or over the counter medications (except paracetamol [up to 2 g&#xD;
             per day]), including herbal or nutritional supplements, within 14 days before the&#xD;
             first dose of study drug or throughout the study.&#xD;
&#xD;
          -  The subject has consumed grapefruit or grapefruit juice, Seville orange or Seville&#xD;
             orange containing products (eg, marmalade), or caffeine- or xanthine containing&#xD;
             products within 48 hours before the first dose of study drug or throughout the study.&#xD;
&#xD;
          -  The subject is a smoker or has used nicotine or nicotine-containing products (eg,&#xD;
             snuff, nicotine patch, nicotine chewing gum, mock cigarettes, or inhalers) within 6&#xD;
             months before the first dose of study drug.&#xD;
&#xD;
          -  The subject has a history of alcohol abuse or drug addiction within the last year or&#xD;
             excessive alcohol consumption (regular alcohol intake &gt;21 units per week for male&#xD;
             subjects and &gt;14 units of alcohol per week for female subjects) (1 unit is equal to&#xD;
             approximately Â½ pint [200 mL] of beer, 1 small glass [100 mL] of wine, or 1 measure&#xD;
             [25 mL] of spirits).&#xD;
&#xD;
          -  The subject has a positive test result for drugs of abuse, alcohol, or cotinine&#xD;
             (indicating active current smoking) at screening or before the first dose of study&#xD;
             drug.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Younghwan Jang</last_name>
    <phone>82-2-6987-4154</phone>
    <email>younghj@lgchem.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>PPD</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 9, 2021</study_first_submitted>
  <study_first_submitted_qc>May 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 13, 2021</study_first_posted>
  <last_update_submitted>May 12, 2021</last_update_submitted>
  <last_update_submitted_qc>May 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bioavailability</keyword>
  <keyword>relative</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperuricemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>To be determined</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

